» Articles » PMID: 29538741

Triazole Resistance Surveillance in Aspergillus Fumigatus

Overview
Journal Med Mycol
Date 2018 Mar 15
PMID 29538741
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Triazole resistance is an increasing concern in the opportunistic mold Aspergillus fumigatus. Resistance can develop through exposure to azole compounds during azole therapy or in the environment. Resistance mutations are commonly found in the Cyp51A-gene, although other known and unknown resistance mechanisms may be present. Surveillance studies show triazole resistance in six continents, although the presence of resistance remains unknown in many countries. In most countries, resistance mutations associated with the environment dominate, but it remains unclear if these resistance traits predominately migrate or arise locally. Patients with triazole-resistant aspergillus disease may fail to antifungal therapy, but only a limited number of cohort studies have been performed that show conflicting results. Treatment failure might be due to diagnostic delay or due to the limited number of alternative treatment options. The ISHAM/ECMM Aspergillus Resistance Surveillance working group was set up to facilitate surveillance studies and stimulate international collaborations. Important aims are to determine the resistance epidemiology in countries where this information is currently lacking, to gain more insight in the clinical implications of triazole resistance through a registry and to unify nomenclature through consensus definitions.

Citing Articles

Distribution and Epidemiological Characteristics of Clinical Isolates of in a Hospital from 2021 to 2023: A Retrospective Study.

You Z, Yan Y, Fu T, Yang X, Li Z, Zhou L Infect Drug Resist. 2025; 18:1199-1208.

PMID: 40040851 PMC: 11878120. DOI: 10.2147/IDR.S507944.


The impact of climate change on the epidemiology of fungal infections: implications for diagnosis, treatment, and public health strategies.

George M, Gaitor T, Cluck D, Henao-Martinez A, Sells N, Chastain D Ther Adv Infect Dis. 2025; 12:20499361251313841.

PMID: 39944519 PMC: 11815821. DOI: 10.1177/20499361251313841.


Understanding the clinical and environmental drivers of antifungal resistance in the One Health context.

Williams C, Gregory J, Usher J Microbiology (Reading). 2024; 170(10).

PMID: 39475703 PMC: 11524418. DOI: 10.1099/mic.0.001512.


Unveiling environmental transmission risks: comparative analysis of azole resistance in clinical and environmental isolates from Yunnan, China.

Gong J, Huang J, Liu Y, Zhang Y, Gao Y Microbiol Spectr. 2024; :e0159424.

PMID: 39470286 PMC: 11619395. DOI: 10.1128/spectrum.01594-24.


Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches.

Pham D, Sivalingam V, Tang H, Montgomery J, Chen S, Halliday C J Fungi (Basel). 2024; 10(7).

PMID: 39057332 PMC: 11278267. DOI: 10.3390/jof10070447.